Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer

Okubo,Mitsuru; Nakayama,Hidetugu; Itonaga,Tomohiro; Tajima,Yu; Shiraishi,Sachika; Mikami,Ryuji; Sakurada,Akira; Sugahara,Shinji; Koizumi,Kiyoshi; Tokuuye,Koichi

doi:10.3892/ol.2015.3216

Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer

Authors:
- Mitsuru Okubo
- Hidetugu Nakayama
- Tomohiro Itonaga
- Yu Tajima
- Sachika Shiraishi
- Ryuji Mikami
- Akira Sakurada
- Shinji Sugahara
- Kiyoshi Koizumi
- Koichi Tokuuye
View Affiliations

Affiliations: Department of Radiology, Tokyo Medical University Hospital, Shinjuku‑ku, Tokyo 160‑0023, Japan
Published online on: May 18, 2015 https://doi.org/10.3892/ol.2015.3216
Pages: 255-259

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

External-beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT) is known to provide improved survival outcomes compared with EBRT alone in the treatment of prostate cancer; however, the use of ADT has been reported to be associated with adverse events. Accordingly, the aim of the present study was to clarify the adequate duration of ADT when combined with EBRT to treat patients with high‑risk localized prostate cancer, with consideration of survival outcomes and toxicity. Between 2001 and 2011, 173 patients with high‑risk localized prostate cancer received ADT combined with EBRT, at a median dose of 69.6 Gy. Of these, 54 (31%) underwent short‑term ADT (<36 months) and 119 (69%) underwent long‑term ADT (≥36 months). During the median follow‑up period of 54 months, the five‑year progression‑free survival rate of patients receiving short‑term ADT (72.9%) was significantly lower than that of patients receiving long‑term ADT (92.8%) (P<0.01). Furthermore, the incidence of cardiovascular toxicity at grade II or above was significantly higher amongst patients treated with short‑term ADT compared with patients treated with long‑term ADT (P<0.01). Thus, the present study determined that ADT for ≥36 months combined with EBRT significantly improved the progression‑free survival of patients with high-risk localized prostate cancer and exhibited an acceptable toxicity profile.

View Figures

View References

1	Watanabe H: Mass screening program for prostatic cancer in Japan. Int J Clin Oncol. 6:66–73. 2001.PubMed/NCBI
2	Ogawa K, Nakamura K, Onishi H, et al: Japanese Patterns of Care Study Working Subgroup of Prostate Cancer: Radical external beam radiotherapy for prostate cancer in Japan: results of the 1999–2001 patterns of care process survey. Jpn J Clin Oncol. 36:40–45. 2006. View Article : Google Scholar : PubMed/NCBI
3	Marugame T and Mizuno S: Comparison of prostate cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO mortality database (1960–2000). Jpn J Clin Oncol. 35:690–691. 2005. View Article : Google Scholar : PubMed/NCBI
4	Bolla M, Van Tienhoven G, Warde P, et al: External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 11:1066–1073. 2010. View Article : Google Scholar : PubMed/NCBI
5	D'Amico AV, Chen MH, Renshaw AA, Loffredo M and Kantoff PW: Androgen suppression and radiation vs. radiation alone for prostate cancer: a randomized trial. JAMA. 299:289–295. 2008.PubMed/NCBI
6	Jones CU, Hunt D, McGowan DG, et al: Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 365:107–118. 2011. View Article : Google Scholar : PubMed/NCBI
7	D'Amico AV, Denham JW, Crook J, et al: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 25:2420–2425. 2007. View Article : Google Scholar : PubMed/NCBI
8	Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D and Pollack A: Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 62:397–405. 2005. View Article : Google Scholar : PubMed/NCBI
9	Bolla M, de Reijke TM, Van Tienhoven G, et al: EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 360:2516–2527. 2009. View Article : Google Scholar : PubMed/NCBI
10	Kuban DA, Thames HD, Levy LB, et al: Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 57:915–928. 2003. View Article : Google Scholar : PubMed/NCBI
11	Sobin LH and Wittekind CH; International Union Against Cancer (UICC). TNM Classification of Malignant Tumors. 6th. Wiley; New York, NY: 2002
12	Roach M III, Hanks G, Thames H Jr, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 65:965–974. 2006. View Article : Google Scholar : PubMed/NCBI
13	Trotti A, Colevas AD, Setser A, et al: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
14	Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
15	Epstein JI, Allsbrook WC Jr, Amin MB and Egevad LL: ISUP Grading Committee: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 29:1228–1242. 2005. View Article : Google Scholar : PubMed/NCBI
16	Mottet N, Peneau M, Mazeron JJ, Molinie V and Richaud P: Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol. 62:213–219. 2012. View Article : Google Scholar : PubMed/NCBI
17	Warde P, Mason M, Ding K, et al: NCIC CTG PR.3/MRC UK PR07 Investigators: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 378:2104–2111. 2011. View Article : Google Scholar : PubMed/NCBI
18	Widmark A, Klepp O, Solberg A, et al: Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 373:301–308. 2009. View Article : Google Scholar : PubMed/NCBI
19	Albertsen PC, Hanley JA, Barrows GH, et al: Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 97:1248–1253. 2005. View Article : Google Scholar : PubMed/NCBI
20	Horwitz EM, Bae K, Hanks GE, et al: Ten-year follow-up of radiation therapy oncology group protocol 92–02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 26:2497–2504. 2008. View Article : Google Scholar : PubMed/NCBI
21	Nanda A, Chen MH, Braccioforte MH, Moran BJ and D'Amico AV: Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 302:866–873. 2009. View Article : Google Scholar : PubMed/NCBI
22	Lawton CA, DeSilvio M, Roach M III, et al: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94–13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 69:646–655. 2007. View Article : Google Scholar : PubMed/NCBI